Given that IL-17A has been demonstrated to be tightly linked to the development of cardiovascular diseases (Kamat et al., 2015; Madhur et al., 2010; Madhur et al., 2011; Saleh et al., 2016; Kuwabara et al., 2017; Nguyen et al., 2013), these data imply the possibility of IL-17A mediating the cardiovascular sequelae of RSDS. The gene discussed is IL17A; the disease is complex regional pain syndrome type 1.